Invivyd Initiates Phase 2 Trial for VYD2311 in Long COVID and Vaccine Injury.

Invivyd and the SPEAR Study Group plan to initiate a Phase 2 clinical trial evaluating monoclonal antibody VYD2311 in individuals with Long COVID or COVID vaccine injury. The trial will assess safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with chronic infection or antigen persistence in various tissues, and those with COVID vaccine-induced spike protein persistence. The study will include multiple active antibody doses administered over the long term to assess safety and potential clinical benefit of VYD2311 treatment versus placebo.